| Literature DB >> 32790115 |
Sunny Z Wu1,2, Daniel L Roden1,2, Chenfei Wang3, Holly Holliday1,2, Kate Harvey1, Aurélie S Cazet1,2, Kendelle J Murphy1,2, Brooke Pereira1,2, Ghamdan Al-Eryani1,2, Nenad Bartonicek1,2, Rui Hou4, James R Torpy1,2, Simon Junankar1,2, Chia-Ling Chan5, Chuan En Lam5, Mun N Hui1,6, Laurence Gluch7, Jane Beith6, Andrew Parker8, Elizabeth Robbins9, Davendra Segara8, Cindy Mak6, Caroline Cooper10,11, Sanjay Warrier12,13, Alistair Forrest4,14, Joseph Powell5,15, Sandra O'Toole1,2,16, Thomas R Cox1,2, Paul Timpson1,2, Elgene Lim1,2,8, X Shirley Liu3, Alexander Swarbrick1,2.
Abstract
The tumour stroma regulates nearly all stages of carcinogenesis. Stromal heterogeneity in human triple-negative breast cancers (TNBCs) remains poorly understood, limiting the development of stromal-targeted therapies. Single-cell RNA sequencing of five TNBCs revealed two cancer-associated fibroblast (CAF) and two perivascular-like (PVL) subpopulations. CAFs clustered into two states: the first with features of myofibroblasts and the second characterised by high expression of growth factors and immunomodulatory molecules. PVL cells clustered into two states consistent with a differentiated and immature phenotype. We showed that these stromal states have distinct morphologies, spatial relationships and functional properties in regulating the extracellular matrix. Using cell signalling predictions, we provide evidence that stromal-immune crosstalk acts via a diverse array of immunoregulatory molecules. Importantly, the investigation of gene signatures from inflammatory-CAFs and differentiated-PVL cells in independent TNBC patient cohorts revealed strong associations with cytotoxic T-cell dysfunction and exclusion, respectively. Such insights present promising candidates to further investigate for new therapeutic strategies in the treatment of TNBCs.Entities:
Keywords: cancer-associated fibroblasts; single-cell RNA sequencing; stromal heterogeneity; triple-negative breast cancer; tumour microenvironment
Mesh:
Year: 2020 PMID: 32790115 PMCID: PMC7527929 DOI: 10.15252/embj.2019104063
Source DB: PubMed Journal: EMBO J ISSN: 0261-4189 Impact factor: 11.598